- Home
- CTO vs CGEM Comparison
CTO vs CGEM Comparison
Compare CTO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- CGEM
- Stock Information
- Founded
- CTO 1902
- CGEM 2016
- Country
- CTO United States
- CGEM United States
- Employees
- CTO N/A
- CGEM N/A
- Industry
- CTO Real Estate Investment Trusts
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- CGEM Health Care
- Exchange
- CTO Nasdaq
- CGEM Nasdaq
- Market Cap
- CTO 589.6M
- CGEM 490.3M
- IPO Year
- CTO N/A
- CGEM 2021
- Fundamental
- Price
- CTO $18.44
- CGEM $8.65
- Analyst Decision
- CTO Strong Buy
- CGEM Strong Buy
- Analyst Count
- CTO 3
- CGEM 4
- Target Price
- CTO $22.33
- CGEM $32.00
- AVG Volume (30 Days)
- CTO 217.7K
- CGEM 450.4K
- Earning Date
- CTO 07-24-2025
- CGEM 05-08-2025
- Dividend Yield
- CTO 8.25%
- CGEM N/A
- EPS Growth
- CTO N/A
- CGEM N/A
- EPS
- CTO N/A
- CGEM N/A
- Revenue
- CTO $132,203,000.00
- CGEM N/A
- Revenue This Year
- CTO $19.25
- CGEM N/A
- Revenue Next Year
- CTO $8.47
- CGEM N/A
- P/E Ratio
- CTO N/A
- CGEM N/A
- Revenue Growth
- CTO 17.48
- CGEM N/A
- 52 Week Low
- CTO $16.12
- CGEM $6.85
- 52 Week High
- CTO $21.15
- CGEM $24.76
- Technical
- Relative Strength Index (RSI)
- CTO 56.02
- CGEM 62.37
- Support Level
- CTO $17.46
- CGEM $7.73
- Resistance Level
- CTO $18.35
- CGEM $8.00
- Average True Range (ATR)
- CTO 0.31
- CGEM 0.51
- MACD
- CTO 0.06
- CGEM 0.12
- Stochastic Oscillator
- CTO 87.11
- CGEM 89.92
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.